BioSpace News Archive

Conformal Medical, Inc. , a privately held medical device company developing next generation left atrial appendage closure (LAAC) technology, today announced positive clinical data from First-in-Human studies pe

On September 24 , 111, Inc. (NASDAQ: YI) (the “Company” or “111") and Hainan Huluwa Pharmaceutical Group Co., Ltd. (SH: 605199) (“Huluwa Pharmaceutical”) signed a strategic partnership agreement in Shanghai . Mrs. LIU Jingping, Chairperson of Huluwa Pharmaceutical, and Dr. YU Gang, Co-founder and Executive Chairman of 111, attended

Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share. In connection with the offering, Eargo has granted the underwriters a 30-day option to purchase up to an additional 1,177,777 shares of common stock at the initial public offering

Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $12.00 per share, for gross proceeds of $15,000,000, before deducting underwriting discounts, com

Acquisition expands Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s promising preclinical SARM1 programs for axonal degeneration [15-October-2020] INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-he

OpenEye Scientific and Beacon Discovery today announced the rapid identification of two novel chemical entities and more than 30 potent hits for known G-Protein Coupled Receptor (GPCR) targets using Gigadocking™ in OpenEye’s Orion™ molecular design cloud platform.

Synthego, the genome engineering company, has collaborated with The Krogan Lab, a world-renowned scientific research unit at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), to deliver multiple CRISPR-based engineered cell lines to accelerate the study of potential treatment targets for SARS-CoV-2,

PartsSource, the world’s largest, evidence-based marketplace for medical equipment products and services, today launched its latest clinical resource management platform aimed at helping medical equipment suppliers leverage the sheer scale of the PartsSource.com marketplace to improve quality, deliverability, and performance across 3,500 hospitals and health systems.

Parents and caregivers should not use any products containing benzocaine in children under two years of age because of the risk of MetHb.

Medicare Advantage plans in 92 cities will be recognized for exceptional value in the design of their medical and Part D prescription drug benefits available effective January 1.